Advertisement
Screener

Cartesian Therapeutics, Inc. (RNAC) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

Cartesian Therapeutics, Inc. Increase (Decrease) in Deferred Revenue

Cartesian Therapeutics, Inc. (RNAC) reported Increase (Decrease) in Deferred Revenue of -$88.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-08.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-08-08

  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$88.00K.
  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was $2.50M, a 74.57% decline year-over-year.
  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $24.00K.
  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2017 was $2.43M, a 76.64% decline from fiscal 2016.
  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2016 was $10.41M.
  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2015 was -$507.00K.
  • Cartesian Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2014 was -$20.00K.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2018-06-30-$88.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$88.00K
10-Q · filed 2018-08-08
$2.41M
derived: sum of 3 quarters · filed 2018-08-08
$2.43M
derived: sum of 4 quarters · filed 2018-08-08
2018-03-31$0.00
10-Q · filed 2018-05-09
$2.50M
derived: sum of 2 quarters · filed 2018-05-09
$2.52M
derived: sum of 3 quarters · filed 2018-05-09
$2.38M
derived: sum of 4 quarters · filed 2018-08-08
2017-12-31$2.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$2.52M
derived: sum of 2 quarters · filed 2018-03-15
$2.38M
derived: sum of 3 quarters · filed 2018-08-08
$2.43M
10-K · filed 2018-03-15
2017-09-30$24.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
-$123.00K
derived: sum of 2 quarters · filed 2018-08-08
-$66.00K
10-Q · filed 2017-11-07
$9.76M
derived: sum of 4 quarters · filed 2018-08-08
2017-06-30-$147.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$90.00K
10-Q · filed 2018-08-08
$9.73M
derived: sum of 3 quarters · filed 2018-08-08
$9.39M
derived: sum of 4 quarters · filed 2018-08-08
2017-03-31$57.00K
10-Q · filed 2018-05-09
$9.88M
derived: sum of 2 quarters · filed 2018-05-09
$9.53M
derived: sum of 3 quarters · filed 2018-05-09
$10.08M
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31$9.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$9.48M
derived: sum of 2 quarters · filed 2018-03-15
$10.02M
derived: sum of 3 quarters · filed 2018-03-15
$10.41M
10-K · filed 2018-03-15
2016-09-30-$347.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$200.00K
derived: sum of 2 quarters · filed 2017-11-07
$586.00K
10-Q · filed 2017-11-07
$113.00K
derived: sum of 4 quarters · filed 2018-03-15
2016-06-30$547.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
$933.00K
10-Q · filed 2017-08-11
$460.00K
derived: sum of 3 quarters · filed 2018-03-15
-$347.00K
derived: sum of 4 quarters · filed 2018-03-15
2016-03-31$386.00K
10-Q · filed 2017-05-11
-$87.00K
derived: sum of 2 quarters · filed 2018-03-15
-$894.00K
derived: sum of 3 quarters · filed 2018-03-15
2015-12-31-$473.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
-$1.28M
derived: sum of 2 quarters · filed 2018-03-15
-$507.00K
10-K · filed 2018-03-15
2015-09-30-$807.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
-$34.00K
10-Q · filed 2016-11-10
2015-06-30$773.00K
10-Q · filed 2016-08-09
2014-12-31-$20.00K
10-K · filed 2017-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23